108 results on '"Martín-Jiménez M"'
Search Results
2. Incidence of venous thromboembolism in patients with colorectal cancer according to oncogenic status
3. New remains from the Spanish Cenomanian shed light on the Gondwanan origin of European Early Cretaceous titanosaurs
4. Systematic study of the historical material of Upper Cretaceous reptiles from the Tremp Basin (Catalonia, Spain) housed at the Museo Nacional de Ciencias Naturales (Madrid)
5. 216P Relationship between regulatory T lymphocytes (Treg): Related genes and pathological response to neoadjuvant docetaxel-carboplatin in early-stage triple-negative breast cancer (TNBC)
6. LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial
7. Clinical guide SEOM on venous thromboembolism in cancer patients
8. Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana’s predictive model
9. PO-56 Relationship between clinical presentation of SARS-CoV-2 infection and risk of thromboembolic events and prognosis in cancer patients
10. LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
11. 233P Germline genetic testing before formal counseling: Impact in cancer management in a Spanish university hospital
12. 1654P Circulating tumor cells (CTCs) as prognostic factor for pancreatic cancer: Updated of a prospective study
13. 1648P Association between circulating tumor cell count and thrombosis in pancreatic cancer
14. 413P Characteristics of patients (pts) with previously treated, oestrogen receptor-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) who had rapid progression (RP) in acelERA BC
15. 251P Body mass index as a predictive factor for efficacy of taxane-based chemotherapy in early breast cancer patients
16. A new Iberian pleurosternid (Jurassic-Cretaceous transition, Spain) and first neuroanatomical study of this clade of stem turtles
17. PO-58 Venous and arterial tromboembolic events among hospitalized cancer patients with SARS-COV2 infection
18. OC-02 Khorana risk score at diagnosis of SARS-CoV-2 infection as a predicting tool for venous thromboembolic disease development, and overall mortality, in cancer patients
19. A new Iberian pleurosternid (Jurassic-Cretaceous transition, Spain) and first neuroanatomical study of this clade of stem turtles.
20. 273TiP ACE-Breast-03: A phase II study patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens treated with ARX788
21. 1589P Chronological pattern of venous thromboembolism (VTE) occurrence impacts in survival of pancreatic ductal adenocarcinoma (PDAC)
22. 211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study
23. 141MO Pathological response and early survival data according to TNBCtype4 classifier in operable triple-negative breast cancer (TNBC) treated with neoadjuvant carboplatin and docetaxel
24. LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)
25. 207TiP Phase III study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)
26. 162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer
27. 62P Outcomes of high-risk breast cancer (BC) patients from El Álamo IV registry and GEICAM adjuvant clinical trials
28. 60MO Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B
29. 44P Biomarker analysis from a phase Ib, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into metastatic and primary liver tumors
30. 229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study
31. Breast cancer in Spain
32. 142P Quality-adjusted survival with ribociclib plus fulvestrant (R+F) versus placebo plus fulvestrant (P+F) in postmenopausal women (PMW) HR+/HER2- advanced breast cancer (ABC) based on the MONALEESA-3 trial
33. 144P Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3)
34. 143P Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study
35. 83P Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+ HR+ breast cancer after trastuzumab-based therapy on patient outcomes
36. 23P Clinical, pathological and gene expression features of HER2-low breast cancer
37. Dental students’ knowledge regarding the indications for antibiotics in the management of endodontic infections
38. Systematic study of the historical material of Upper Cretaceous reptiles from the Tremp Basin (Catalonia, Spain) housed at the Museo Nacional de Ciencias Naturales (Madrid)
39. Sistemas ultrasónicos para la irrigación del sistema de conductos radiculares
40. 1704PD - Tumor microenvironment biomarkers as therapeutic strategies for TNBC
41. 323TiP - EarLEE-1: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), high-risk, early breast cancer (EBC)
42. 319TiP - CompLEEment-1: Phase 3b study of ribociclib + letrozole for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) in patients with no prior endocrine therapy (ET) for ABC
43. 177P - Effects of neratinib (N) on health-related quality of life (HRQoL) in early-stage HER2+ breast cancer (BC): longitudinal analyses from the phase III ExteNET trial
44. 186P - Breast cancer PAM50 subtypes: Correlation between RNA-Seq and multiplexed gene expression platforms
45. 184P - Distribution of genomically defined recurrence risk in luminal A and B breast tumors defined by inmunohistochemistry: A retrospective study in Spanish population
46. 148O - Phase III evaluating the addition of fulvestrant (F) to anastrozol (A) as adjuvant therapy in postmenopausal women with hormone receptor positive HER2 negative (HR+/HER2-) early breast cancer (EBC): Results from the GEICAM/2006-10 study
47. 162PD - Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann’s refined classification (TNBCtype-4)
48. 149O - Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial
49. Dental students' knowledge regarding the indications for antibiotics in the management of endodontic infections.
50. Sistemas ultrasónicos para la irrigación del sistema de conductos radiculares
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.